Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines

Abstract

2',2'-Difluorodeoxycytidine (gemcitabine, dFdC) and cis-diammine-dichloroplatinum (cisplatin, CDDP) are active agents against ovarian cancer and non-small-cell lung cancer (NSCLC). CDDP acts by formation of platinum (Pt)-DNA adducts; dFdC by dFdCTP incorporation into DNA, subsequently leading to inhibition of exonuclease and DNA repair. Previously, synergism between both compounds was found in several human and murine cancer cell lines when cells were treated with these drugs in a constant ratio. In the present study we used different combinations of both drugs (one drug at its IC25 and the other in a concentration range) in the human ovarian cancer cell line A2780, its CDDP-resistant variant ADDP, its dFdC-resistant variant AG6000 and two NSCLC cell lines, H322 (human) and Lewis lung (LL) (murine). Cells were exposed for 4, 24 and 72 h with a total culture time of 96 h, and possible synergism was evaluated by median drug effect analysis by calculating a combination index (CI; CI 25% more DNA strand breaks (DSB) than each drug alone; however, in the other cell lines no effect, or even a decrease in DSB, was observed. dFdC increased the cellular Pt accumulation after 24 h incubation only in the ADDP cell line. However, dFdC did enhance the Pt-DNA adduct formation in the A2780, AG6000, ADDP and LL cell lines (1.6-, 1.4-, 2.9- and 1.6-fold respectively). This increase in Pt-DNA adduct formation seems to be related to the incorporation of dFdC into DNA (r = 0.91). No increase in DNA platination was found in the H322 cell line. dFdC only increased Pt-DNA adduct retention in the A2780 and LL cell lines, but decreased the Pt-DNA adduct retention in the AG6000 cell line. In conclusion, the synergism between dFdC and CDDP appears to be mainly due to an increase in Pt-DNA adduct formation possibly related to changes in DNA due to dFdC incorporation into DNA.

References 30

1. 1.

   Abbruzzese J. L., Frost P. Studies on the mechanism of the synergistic interaction between 2'-deoxy-5-azacytidine and cisplatin. Cancer Chemother Pharmacol. 1992;30(1):31-36.

   Not in our library10.1007/bf00686482

2. 2.

   Abbruzzese J. L., Grunewald R., Weeks E. A., Gravel D., Adams T., Nowak B., Mineishi S., Tarassoff P., Satterlee W., Raber M. N. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol. 1991;9(3):491-498.

   Not in our library10.1200/jco.1991.9.3.491

3. 3.

   Abratt R. P., Bezwoda W. R., Goedhals L., Hacking D. J. Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol. 1997;15(2):744-749.

   Not in our library10.1200/jco.1997.15.2.744

4. 4.

   Bergman A. M., Ruiz van Haperen V. W., Veerman G., Kuiper C. M., Peters G. J. Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res. 1996;2(3):521-530.

   Not in our library

5. 5.

   Birnboim H. C., Jevcak J. J. Fluorometric method for rapid detection of DNA strand breaks in human white blood cells produced by low doses of radiation. Cancer Res. 1981;41(5):1889-1892.

   Not in our library

6. 6.

   Chiu C. S., Chan A. K., Wright J. A. Inhibition of mammalian ribonucleotide reductase by cis-diamminedichloroplatinum(II). Biochem Cell Biol. 1992;70(12):1332-1338.

   Not in our library10.1139/o92-181

7. 7.

   Chou T. C., Motzer R. J., Tong Y., Bosl G. J. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst. 1994;86(20):1517-1524.

   Not in our library10.1093/jnci/86.20.1517

8. 8.

   Crinò L., Scagliotti G., Marangolo M., Figoli F., Clerici M., De Marinis F., Salvati F., Cruciani G., Dogliotti L., Pucci F. Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol. 1997;15(1):297-303.

   Not in our library10.1200/jco.1997.15.1.297

9. 9.

   Ellerhorst J. A., Frost P., Abbruzzese J. L., Newman R. A., Chernajovsky Y. 2'-deoxy-5-azacytidine increases binding of cisplatin to DNA by a mechanism independent of DNA hypomethylation. Br J Cancer. 1993;67(2):209-215.

   Not in our library10.1038/bjc.1993.41

10. 10.

    Freeman K. B., Anliker S., Hamilton M., Osborne D., Dhahir P. H., Nelson R., Allerheiligen S. R. Validated assays for the determination of gemcitabine in human plasma and urine using high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Appl. 1995;665(1):171-181.

    Not in our library10.1016/0378-4347(94)00521-6

11. 11.

    Heinemann V., Hertel L. W., Grindey G. B., Plunkett W. Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. Cancer Res. 1988;48(14):4024-4031.

    Not in our library

12. 12.

    Huang P., Chubb S., Hertel L. W., Grindey G. B., Plunkett W. Action of 2',2'-difluorodeoxycytidine on DNA synthesis. Cancer Res. 1991;51(22):6110-6117.

    Not in our library

13. 13.

    Lu Y., Han J., Scanlon K. J. Biochemical and molecular properties of cisplatin-resistant A2780 cells grown in folinic acid. J Biol Chem. 1988;263(10):4891-4894.

    Not in our library

14. 14.

    Monks A., Scudiero D., Skehan P., Shoemaker R., Paull K., Vistica D., Hose C., Langley J., Cronise P., Vaigro-Wolff A. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst. 1991;83(11):757-766.

    Not in our library10.1093/jnci/83.11.757

15. 15.

    Parker R. J., Gill I., Tarone R., Vionnet J. A., Grunberg S., Muggia F. M., Reed E. Platinum-DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absorption spectrometry. Carcinogenesis. 1991;12(7):1253-1258.

    Not in our library10.1093/carcin/12.7.1253

16. 16.

    Peters G. J., Laurensse E., Leyva A., Pinedo H. M. Purine nucleosides as cell-specific modulators of 5-fluorouracil metabolism and cytotoxicity. Eur J Cancer Clin Oncol. 1987;23(12):1869-1881.

    Not in our library10.1016/0277-5379(87)90053-8

17. 17.

    Peters G. J., Schornagel J. H., Milano G. A. Clinical pharmacokinetics of anti-metabolites. Cancer Surv. 1993;17:123-156.

    Not in our library

18. 18.

    Peters G. J., Wets M., Keepers Y. P., Oskam R., van Ark-Otte J., Noordhuis P., Smid K., Pinedo H. M. Transformation of mouse fibroblasts with the oncogenes H-ras OR trk is associated with pronounced changes in drug sensitivity and metabolism. Int J Cancer. 1993;54(3):450-455.

    Not in our library10.1002/ijc.2910540316

19. 19.

    Ruiz van Haperen V. W., Veerman G., Boven E., Noordhuis P., Vermorken J. B., Peters G. J. Schedule dependence of sensitivity to 2',2'-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours. Biochem Pharmacol. 1994;48(7):1327-1339.

    Not in our library10.1016/0006-2952(94)90554-1

20. 20.

    Ruiz van Haperen V. W., Veerman G., Eriksson S., Boven E., Stegmann A. P., Hermsen M., Vermorken J. B., Pinedo H. M., Peters G. J. Development and molecular characterization of a 2',2'-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780. Cancer Res. 1994;54(15):4138-4143.

    Not in our library

21. 21.

    Ruiz van Haperen V. W., Veerman G., Vermorken J. B., Peters G. J. 2',2'-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines. Biochem Pharmacol. 1993;46(4):762-766.

    Not in our library10.1016/0006-2952(93)90566-f

22. 22.

    Scanlon K. J., Kashani-Sabet M., Tone T., Funato T. Cisplatin resistance in human cancers. Pharmacol Ther. 1991;52(3):385-406.

    Not in our library10.1016/0163-7258(91)90033-i

23. 23.

    Steward W. P., Dunlop D. J., Dabouis G., Lacroix H., Talbot D. Phase I/II study of gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer: preliminary results. Semin Oncol. 1996;23(5 Suppl 10):43-47.

    Not in our library

24. 24.

    Terheggen P. M., Emondt J. Y., Floot B. G., Dijkman R., Schrier P. I., den Engelse L., Begg A. C. Correlation between cell killing by cis-diamminedichloroplatinum(II) in six mammalian cell lines and binding of a cis-diamminedichloroplatinum(II)-DNA antiserum. Cancer Res. 1990;50(12):3556-3561.

    Not in our library

25. 25.

    Vermorken J. B., van der Vijgh W. J., Klein I., Gall H. E., van Groeningen C. J., Hart G. A., Pinedo H. M. Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin. Clin Pharmacol Ther. 1986;39(2):136-144.

    Not in our library10.1038/clpt.1986.24

26. 26.

    van Haperen V. W., Veerman G., Vermorken J. B., Pinedo H. M., Peters G. Regulation of phosphorylation of deoxycytidine and 2',2'-difluorodeoxycytidine (gemcitabine); effects of cytidine 5'-triphosphate and uridine 5'-triphosphate in relation to chemosensitivity for 2',2'-difluorodeoxycytidine. Biochem Pharmacol. 1996;51(7):911-918.

    Not in our library10.1016/0006-2952(95)02402-6

27. 27.

    van Moorsel CJ, Peters GJ, Pinedo HM. Gemcitabine: Future Prospects of Single-Agent and Combination Studies. Oncologist. 1997;2(3):127-134.

    Not in our library

28. 28.

    van der Vijgh W. J. Clinical pharmacokinetics of carboplatin. Clin Pharmacokinet. 1991;21(4):242-261.

    Not in our library10.2165/00003088-199121040-00002

29. 29.

    van der Wilt C. L., Smid K., Aherne G. W., Noordhuis P., Peters G. J. Biochemical mechanisms of interferon modulation of 5-fluorouracil activity in colon cancer cells. Eur J Cancer. 1997;33(3):471-478.

    Not in our library10.1016/s0959-8049(97)89024-7

30. 30.

    van der Wilt C. L., Visser G. W., Braakhuis B. J., Wedzinga R., Noordhuis P., Smid K., Peters G. J. In vitro antitumour activity of cis- and trans-5-fluoro-5,6-dihydro-6-alkoxy-uracils; effects on thymidylate synthesis. Br J Cancer. 1993;68(4):702-707.

    Not in our library10.1038/bjc.1993.413

Cited by papers we hold 1

• Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials · 2007
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.